More Adults With Type 1 Diabetes Achieved A1C Goal (

Core Insights - MannKind Corporation announced positive 30-week results from the Phase 4 INHALE-3 study, showing that more patients with type 1 diabetes achieved target A1c levels when using Afrezza compared to usual care [1][3] Study Overview - The INHALE-3 study is a randomized controlled trial that included a 17-week phase followed by a 13-week extension, conducted across 19 U.S. sites with 141 enrolled patients [3][4] - Participants were adults with type 1 diabetes using multiple daily injections, automated insulin delivery systems, or pumps without automation, assigned to either continue standard care or switch to Afrezza [3][4] Key Findings - The extension phase showed a 100% increase in the number of subjects achieving A1c levels below 7% at 30 weeks in the Afrezza-treated group compared to baseline [1] - The study met its primary efficacy endpoint at 17 weeks, demonstrating non-inferiority in HbA1c change between the Afrezza group and the usual care group [4] - In the extension phase, 45 subjects from the inhaled insulin group and 49 from the usual care group transitioned to Afrezza, with 43 and 42 completing the study respectively [4] Future Outlook - MannKind Corporation plans to present more detailed results from the 30-week study at the ATTD conference in March 2025 [3]